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In the United States, over 8 billion chickens and 220 million domestic turkeys are sold for human food consumption on an annual basis. 2 In comparison, 37 million quail, 4 million chukars, 10 million pheasants, and 1 million mallard ducks are reportedly sold for food. 1 Veterinarians who treat game birds need access to therapeutic drugs and need to be able to provide appropriate WDIs to ensure that drug residues will not enter the food chain. The purpose of this digest is to familiarize veterinarians with the few drugs that are approved for use in game birds and to provide information on the status of ELDU in these species.
Classification of Game Birds as Minor Food-Producing Species
Under the FDA' s definition, birds, other than chickens or turkeys, are considered a minor species. 3 One of the major challenges for obtaining approval of veterinary products for use in minor species is the minimal economic return to the pharmaceutical sponsors because of the small market size. Currently, although there are more than 250 approved drugs for chickens and 45 approved drugs for turkeys, there are only 3 approved drugs for ducks, 5 for pheasants, 2 for chukars, 8 for quail, and 1 for pigeons (Appendix).
Guidelines for ELDU in Game Bird Species
The Animal Medicinal Drug Use Clarification Act states that if an appropriate labeled drug is not available, ELDU is permitted under specific guidelines. 4 The act, however, also expressly prohibits the extralabel use of an approved animal or human drug in or on animal feed. In most commercial settings, it is not feasible to treat flocks on an individual basis. Therefore, treating a large population of game birds necessitates that medication be administered via food or water. Although medicated water may be allowed under AMDUCA, this can also be impractical if husbandry practices allow birds to preferentially drink pooled rainwater over medicated water. The FDA has recognized the difficulty of this situation for minor species such as game birds and farmed fish and has adopted a CPG for the extralabel use of medicated feeds. 5 According to the CPG, "extra-label use of medicated feed for treatment of minor species may be considered when the health of the animals is threatened and suffering or death would result from failure to treat the affected animals." Under veterinary guidance, a medicated feed for a major species can be prescribed for a minor species for up to 6 months. This CPG does not legalize ELDU of medicated feeds, but in circumstances of this nature, the FDA "will not ordinarily consider regulatory action against a veterinarian" provided specific regulations are followed. 5 These regulations include the use of a medicated feed that has already been approved in a major food species; appropriate labeling of feed; record-keeping requirements; confined population requirement; a valid veterinary-client-patient relationship; veterinary supervision; and determination of an appropriate, scientifically based WDI. A more detailed list of criteria and requirements can be found in the CPG Sec 615.115 or on the FARAD Web site. 6 
Current update on drugs for game bird species

Species Considerations
Veterinarians considering ELDU must be aware of adverse effects of the drug and species hypersensitivities or contraindications. Species variations in avian physiology and metabolism can result in substantial variability in pharmacokinetics and toxicoses associated with various drugs. Although only a few studies have explored differences in the metabolism of avian species, a recent study 7 that investigated differences in hepatic cytochrome p450 metabolism in chickens, turkeys, pheasants, and quail found considerable vari- ability in metabolism of midazolam, a known marker substrate for cytochrome p450 microsomal enzymes in mammals. It is important for practitioners to remember that although a medication may be safely used in one or both of the major food-producing avian species (ie, chickens and domestic turkeys), this does not mean that the same drug can be safely or effectively used in a minor food-producing avian species at similar dosages. For example, nitarsone, an arsenical compound used to treat histomoniasis, is approved for use in chickens and turkeys but is listed on the label as dangerous when administered to ducks and geese. Arsenical compounds can also cause hepatic lipidosis and death in waterfowl species when administered at the labeled dose for poultry. 8 Another example is the coccidiostat salinomycin, which has multiple formulations labeled for chickens and one for quail. In turkeys, salinomycin causes lethal muscle degeneration and necrosis.
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9,a Fenbendazole has been determined to be toxic in Columbiformes spp, such as pigeons, causing acute hemorrhagic enteritis. 10, 11 These examples highlight the fact that there are substantial species differences between birds and between birds and nonavian species. Therefore, it is prudent to attempt initial treatment of a small population of animals before treating the entire flock if no species-specific data are available.
Meat WDIs
Few studies have been performed to document how physiologic, metabolic, and excretory differences vary between the major and minor food-producing avian species. When data are lacking in minor avian species, residue and pharmacokinetic data from major avian species are sometimes used to estimate potential residues and WDIs for minor avian species. Extrapolating these data should be done with great caution and in some cases may not be appropriate. FARAD has developed an EWE algorithm 12 that has been used to estimate conservative WDIs in instances where minor food animal species are exposed to drugs in an extralabel manner. The WDI estimates are best performed with complete pharmacokinetic data sets, but such data sets are often difficult to obtain for game birds. However, in situations where pharmacokinetic information for a labeled drug is limited, the EWE algorithm uses halflife multipliers to determine a very conservative WDI. It should be noted, however, that many of these WDI estimates are in accordance with the CPG for the extralabel use of medicated feeds. 5 
Egg WDIs
Drug residues in eggs depend on many factors including blood and tissue half-lives of the drug, character of the drug (eg, protein binding), and species and environmental factor variability in egg development. Egg WDIs are notoriously difficult to establish because of the prolonged process of egg development and the complicated pharmacodynamics of drug uptake and residues within the developing egg. 13 There are few studies available on residues in major avian species, and no definitive studies were found evaluating residues in game bird eggs.
Prohibited Drugs
The FDA has prohibited specific drugs from use in food animals because of human safety concerns associated with the drugs 14 There are also drugs that are prohibited from being used in an extralabel manner including, but not limited to, chloramphenicol, dimetridazole, ipronidazole, other nitroimidazoles, nitrofurans, fluoroquinolones, glycopeptides (eg, vancomycin), adamantine, and neuraminidase inhibitor drugs. Some of these drugs are prohibited from use in all food-producing animals, whereas others are prohibited from extralabel use only.
Enrofloxacin and sarofloxacin are specific examples of drugs prohibited for use in avian species. These fluoroquinolones were labeled for use in chickens and turkeys to treat bacterial infections, including Pasteurella spp and Escherichia coli. These drugs were also reportedly used as a prophylactic treatment for gastroenteritis in poultry 15 In 2005, the avian approval for enrofloxacin was withdrawn by the FDA because of human health concerns. Research in Europe and the United States suggests that the continued use of fluoroquinolones was causing an increase in the development of fluoroquinolone-resistant Campylobacter spp in poultry. 16 These resistant organisms could then be transferred to humans, resulting in fluoroquinoloneresistant human Campylobacter infections. 17 As of June 20, 2006, the FDA has expressly prohibited the use of certain antiviral drugs in poultry. The drugs specified are adamantanes (amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir and zanamivir). These medications are used to treat and prevent influenza viral infections in humans, and use of such drugs in avian species (eg, for H5N1 avian influenza) could encourage the evolution of drug-resistant viruses. Currently, chickens, turkeys, and ducks are the only birds specified by the measure, but other species may be added in the future. Ducks and other waterfowl are of particular concern because of their role as vectors for influenza viruses. 18 Although not expressly prohibited in other avian species, the use of these drugs in any avian population would be questionable given that the same concern for viral resistance could apply.
For further questions regarding potential drug residues for a specific proposed treatment plan in game birds, please contact FARAD at 1-888-US-FARAD or at www.farad.org. FARAD will attempt to provide drug residue information according to available data whenever possible.
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